Table 1 Demographic and clinical characteristics of study subjects with metastatic lung cancer receiving chemotherapy
From: Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
Parameter | Value | |
|---|---|---|
| Â | n = 4068 | |
Age (n,%) | Â | Â |
   18-34 | 20 | 0.5 |
   35-44 | 108 | 2.7 |
   45-54 | 513 | 12.6 |
   55-64 | 1,481 | 36.4 |
   > = 65 | 1,946 | 47.8 |
Geographic region (n,%) | Â | Â |
   Northeast | 538 | 13.2 |
   Northcentral | 1,249 | 30.7 |
   South | 2,071 | 50.9 |
   West | 208 | 5.1 |
Payer type (n,%) | Â | Â |
   HMO | 81 | 2.0 |
   Indemnity | 1,814 | 44.6 |
   PPO | 1,210 | 29.7 |
   POS | 941 | 23.1 |
   Other | 21 | 0.5 |
Comorbidities (n,%) | Â | Â |
   Cerebrovascular Disease | 426 | 10.5 |
   Coronay heart disease | 910 | 22.4 |
   Heart failure | 66 | 1.6 |
   Peripheral arterial disease | 165 | 4.1 |
   Diabetes | 808 | 19.9 |
   Kidney Disease | 60 | 1.5 |
   Liver Disease | 272 | 6.7 |
   Respiratory Disease | 2,384 | 58.6 |
Health care expenditures prior to index date (mean, SD) | Â | Â |
   -365 days | 28,562 | 31,136 |